Specifically, the involvement of the VEGF signalling pathway in cancer progression has highlighted the correlation of increased levels of intratumoral VEGF expression with an unfavorable prognosis or a more aggressive evolution of the disease in various oncological pathologies, such as mCRC, non-small cell lung cancer (NSCLC), metastatic breast cancer (mBC), glioblastoma multiforme (GBM) and ovarian cancer (OC). This evidence concerns the gene VEGFA and ovarian carcinoma.